Share

March 17, 2020; 94 (11) Correction

Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks

Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks

First published March 2, 2020, DOI: https://doi.org/10.1212/WNL.0000000000008670
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
498

Share

See original article:

In the articles “Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks” by Portaccio et al.1 and “Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks” by Portaccio et al.,2 Dr. Amato's affiliations should have included:

 Department NEUROFARBA, University of Florence, Italy

 IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy

The authors regret the error.

References

  1. 1.↵
    1. Portaccio E,
    2. Annovazzi P,
    3. Ghezzi A, et al
    . Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks. Neurology 2018;90:e823–e831.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Portaccio E,
    2. Moiola L,
    3. Martinelli V, et al
    . Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks. Neurology 2018;90:e832–e839.
    OpenUrlAbstract/FREE Full Text

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Alert Me

Recommended articles